Publications and databases
Here is the publication list. The list is chronological so has not much context. Relevant papers are highlighted and commented in the blog and research sections.
We are also committed with open science. From 2024, and when possible, the sample is also attached to the paper.
The full list of publications can also be found here: [PubMed] [Google Scholar]
Fernandez-Egea E, Flanagan RJ, Taylor D, Gaughran F, Lawrie SM, Jenkins C, Smith S, Howes OD and MacCabe JH. Mortality associated with clozapine. What is the evidence? Br J Psychiatry 2024 (editorial)
Fernandez-Egea E, Chen S, Sanguesa E, Gasso E, Biria M, Plaistow J, Jarratt-Barnham I, Segarra N, Mas S, Ribate MP, Garcia CB, Finebarg N, Worbe Y, Cardinal RN, Robbins TW. The role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia. Br J Psychiatry (2024) [paper] [Sample] [blog]
Fernandez-Egea E, McCutcheon RA. Clozapine monitoring requirements: is it time for an update? Br J Psychiatry (in press)
Griffin JD, Diederen KMJ, Haarsma J, Jarratt Barnham IC, Cook BRH, Fernandez-Egea E, Williamson S, van Sprang ED, Gaillard R, Vinckier F, Goodyer IM; NSPN Consortium; Murray GK, Fletcher PC. Distinct alterations in probabilistic reversal learning across at-risk mental state, first episode psychosis and persistent schizophrenia. Sci Rep. 2024 Jul 30;14(1):17614. doi: 10.1038/s41598-024-68004-7. PMID: 39080434; PMCID: PMC11289106
Garcia-Rizo C, Crespo-Facorro B, Oliveira C, Gómez-Revuelta M, Kirkpatrick B, Son JM, de la Hoz LC, Garriga M, Garrido-Torres N, Bernardo M, Fernandez-Egea E, Vázquez-Bourgon J. Anthropometry in antipsychotic-naïve first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples. Schizophr Res. 2024 Apr;266:216-226. doi: 10.1016/j.schres.2024.02.020. Epub 2024 Feb 29. PMID: 38428119.
Sangüesa E, Fernández-Egea E, Concha J, García CB, Ribate MP. Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia. Biomedicines. 2024 Mar 7;12(3):597. doi: 10.3390/biomedicines12030597. PMID: 38540209; PMCID: PMC10967865.
Jarrat-Barnham I, Saleh Y, Hussain M, Fernandez-Egea E. The influence of reward sensitivity on weight in treatment resistant chronic schizophrenia. SJPMH (in press).
Wolpe N, Vituri A, Jones PB, Shahar M, Fernandez-Egea E. The longitudinal structure of negative symptoms in treatment-resistant schizophrenia. Compr Psychiatry 2024, 128:152440.
Kirkpatrick B, Fernandez-Egea. Eli Robins:the grandfather of DSM-III. Eur Neuropsycho 2024.
Wolpe N, Fernandez-Egea E. The structure stability of negative symptoms over time. BJSych Open 2023; 9(6):e208 (editorial).
Pizzol D, Trott M, Butler L, Barnett Y, Ford T, Neufeld SA, Ragnhildstveit A, Parris CN, Underwood BR, López Sánchez GF, Fossey M, Brayne C, Fernandez-Egea E, Fond G, Boyer L, Shin JI, Pardhan S, Smith L.. Relationship between severe mental illness and physical multimorbidity: a meta-analysis and call for action. BMJ Mental Health 2023; 26(1):e300870.
Muñoz-Manchado LI, Perez-Revuelta JI, Banerjee A, Galindo-Guarin L, Bernardo M, González-Saiz F, Villagrán-Moreno JM, Fernández-Egea E. Influence of time to clozapine prescription on the clinical outcome. Schizophrenia Research 2023.
De las cuevas C, Sanz EJ, Gross JA, Correll CU, Verdoux H, Lally J, de Filippis R, Schulte PFJ, Molden E, Arrojo-Romero M, Bostrom AD, Schretsanitis G, Fernandez-Egea E, de Leon J. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other western Europe countries compared to the UK. Schizophrenia Research 2023 (doi 10.1016/j.schres.2023.11.010)
Fernandez Egea E, Mucci A, Lee J, Kirkpatrick B. A new era for the negative symptoms of schizophrenia. Br J Psychiatry 2023;223(1):269-270.
Saleh Y, Jarratt-Barnham I, Petitet P, Fernandez-Egea E, Manohar SG, Husain M. Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment-resistant schizophrenia. Mol Psychiatry. 2023 (in print); doi: 10.1038/s41380-023-02232-7.
Ruan CJ, Olmos I, Ricciardi C, Schoretsanitis G, Vincent PD, Anıl Yağcıoğlu AE, Eap CB, Baptista T, Clark SR, Fernandez-Egea E, Kim SH, Lane HY, Leung J, Maroñas Amigo O, Motuca M, Every-Palmer S, Procyshyn RM, Rohde C, Suhas S, Schulte PFJ, Spina E, Takeuchi H, Verdoux H, Correll CU, Molden E, De Las Cuevas C, de Leon J. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies. Schizo Res (in press)
Bernardo M, Fernandez-Egea E. Consensus by the collective of psychiatrists for the clozapine update. Actas Esp Psychiatry. 2023; 52(3):141-144
Kirkpatrick B, Fernandez-Egea E. Assessment and the concept of negative symptoms. Spanish Journal of Psychiatry and Mental Health. 2023 PMID 38591771
Smith L, López Sánchez GF, Fernandez-Egea E, Ford T, Parris C, Underwood BR, Butler L, Barnett Y, Trott M, Koyanagi A. Eating disorders and physical multimorbidity in the English general population. Eat Weight Disorder
Wolpe N, Chen S, Kirkpatrick B, Jones PB, Jenkins C, Cardinal RN, Fernandez-Egea E. Longitudinal effect of clozapine-induced sedation on motivation in schizophrenia: naturalistic longitudinal study. Br J Psych. 2023; 223(1):295-297
Wagner E, Siskind D, Falkai P, Howes O, Correll C, Lee J, Honer HG, Kane JM, Fernandez-Egea E, Barnes TRE, Hasan A, and TRRIP group. Clozapine optimization: a delphi consensus guideline from the treatment reponse and resistance in psychosis working group. Schizophrenia Bulletin 2023.
Schoretsanitis G, Anıl Yağcıoğlu AE, Ruan CJ, Eap CB, Molden E, Baptista T, Clark SR, Fernandez-Egea E, Kim SH, Lane HY, Leung J, Maroñas Amigo O, Motuca M, Olmos I, Every-Palmer S, Procyshyn RM, Rohde C, Satish S, Schulte PFJ, Spina E, Takeuchi H, Verdoux H, Correll CU, de Leon J. Clozapine ultrarapid metabolism during weak induction probably exists bur requires careful diagnosis. A literature review, five new cases and a proposed definition. Schizophrenia Research (in press).
Fernandez-Egea E & Robbins TW. Bobby Fischer and the delusions of the king of logic. Brain 2022; 145(5):1570-1573
Fernandez-Egea E & Wolpe N. Is it time to change the term negative symptoms? Eur Neuropsychopharmacology 2022; 59:7-8.
Garcia-Rizo C, Garcia-Rizo C, Cabrera B, Bioque M, Mezquida G, Lobo A, Gonzalez-Pinto A, Diaz-Caneja CM, Corripio I, Vieta E, Baeza I, Garcia-Portilla MP, Gutierrez-Fraile M, Rodriguez-Jimenez R, Garriga M, Fernandez-Egea E, Bernardo M; PEPs GROUP. The effect of early life events on glucose levels in first-episode psychosis. Front Endocrinol 2022; 13:983792.
Perry BI, Vandenberghe F, Garrido-Torres N, Osimo EF, Piras M, Vazquez-Bourgon J, Upthegrove R, Grosu C, De La Foz VO, Jones PB, Laaboub N, Ruiz-Veguilla M, Stochl J, Dubath C, Canal-Rivero M, Mallikarjun P, Reymond-Delacrétaz A, Ansermot N, Fernandez-Egea E, Crettol S, Gamma F, Plessen KJ, Conus P, Khandaker GM, Murray GK, Eap CB, Crespo-Facorro. The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: international external validation and site-specific recalibration in two independent European samples. Lancet Reg Health Eur, 2022 (PMID 36039146)
Andres-Olivera P, Turrion C, Fernandez-Egea E, Perez J. A clozapine’s uncharted voyage: five years and a pandemic after the end of the mandatory haematological notifications to the Spanish medicines agency. Rev Psiq Salud Mental (2023) in press.
Paton C, Citrome L, Fernandez-Egea E, Rendora O, Barnes TRE. Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit. Ther Adv Psychopharmacology 2022 (PMID 36051503)
Parkin K, Chen S, Biria M, Plaistow J, Beckwith H, Jarratt-Barnham I, Segarra N, Worbe Y, Fineberg N, Cardinal RN, Robbins TW, Fernandez-Egea E. Clozapine related obsessive-compulsive symptoms and their impact on wellbeing: a naturalistic longitudinal study. Psychological Medicine 2022 (PMID 35469587).
Fernandez-Egea E, Chen S, Jenkins C, Turrion C, Mitchell SP, Dodwell DJF, Mann LM, Deakin JB, Syed ZH, Hafizi S, Zimbron J, Praseedom AS, Cardinal RN. The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications: A 5-Year Naturalistic Study. J Clin Psychopharmacol 2021; 41(5):534-539
Toll A, Blanco L, Berge D, Duran X, Canosa I, Legido T, Marmol F, Pérez – Solà V, Fernández – Egea E, Mané E. Multidimensional predictors of negative symptoms in antipsychotic - naive first - episode psychosis. Journal of Psychiatry and Neuroscience 2022; 47(1):E21-E31.
De Leon J et al. An international adult guideline for making clozapine titration safer by using six ancentry-based personalised dosing titration CRP and clozapine levels. Pharmacopsychiatry 2022; 55(2):73-86.
Atkinson-Clement C, de Liege A, Klein Y, Beranger B, Valabregue R, Delorme C, Rose E, Fernandez-Egea E, Hartmann A, Robbins TW, Worbe Y. The sooner the better: clinical and neural correlates of impulsive choice in Tourette disorder. Translational Psychiatry 2021; 11(1):560.
Chen S, Jones PB, Underwood BR, Fernandez-Egea E, Qin P, Lewis JR, Cardinal RN. Risk factors for excess deaths during lockdown among older users of secondary care mental health services without confirmed COVID-19: A retrospective cohort study. Int J Geriatr Psychiatry 2021; 36(12):1899-1907
Zhukovsky P, Morein-Zamir S, Ziauddeen H, Fernandez-Egea E, Meng C, Regenthal R, Sahakian BJ, Bullmore ET, Robbins TW, Dalley JW, Ersche KD. Prefrontal cortex activation and stopping performance underlie the beneficial effects of atomoxetine on response inhibition in healthy and cocaine use disorder volunteers. Biol Psychiatry Cogn Neurosci Neuroimaging 2021: S2451-9022(21)00252-4.
Fernandez-Egea E. Waiting for Godot or the use of biomarkers in clinical practice. Rev. Psiquiatr Salud Ment. 2021: 14(3):123-124.
Saleh Y, Jarratt-Barnham I, Fernandez-Egea E, Husain M. Mechanism underlying motivation dysfunction in schizophrenia. Front Behav Neurosci. 2021 15:709753.
Rekhi G, Ang MS, Huak CY, Fernandez-Egea E, Kirkpatrick B, Lee J. Defining negative symptoms remission in schizophrenia using the Brief Negative Symptoms Scale. Rev. Psiquiatr Salud mental 2021. doi: 10.1016/j.rpsm.2021.05.003
Alabaf S, Kirkpatrick B, Chen S, Cardinal RN, Fernandez-Egea E. Early versus late risk factors for deficit and nondeficit schizophrenia. Rev Psiquiatr Salud Ment. 2021. doi: 10.1016/j.rpsm.2021.03.002.
Rose E, Chen S, Turrion C, Jenkins C, Cardinal RN, Fernandez-Egea E. Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study. Eur Neuropsychopharmacology 2020 36:160-166.
Nombela C, Fernandez-Egea E, Gine E, Worbe Y, del Rio-hortega J, de Castro F. Women neuroscientists disciples of Pio del Rio-Hortega: the Cajal School spreads in Europe and South America. Frontiers in Neuroanatomy. 2021 15:666938.
Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Lee J, Falkai P, Schneider-Axmann T, Hasan A; TRRIP Working Group*. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bulletin 2020 46(6):1459-1470.
Chen S, She R, Qin P, Kershenbaum A, Fernandez-Egea E, Nelder JR, Chuoxin M, Lewis J, Wang C, Cardinal RN. The medium-term impact of COVID-19 lockdown on referrals to secondary care mental health services: a controlled interrupted time series study. Front Psychiatry. 2020; 11:585915
Martínez-Cao C, García-Álvarez L, Bobes-Bascarán T, de la Fuente-Tomás L, Fernández-Egea E, Velasco Á, González-Blanco L, Zurrón-Madera P, Fonseca-Pedrero E, Sáiz-Martínez PA, García-Portilla MP, Bobes J. Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. Rev Psiquiatr Salud Ment. 2020 Jun 4:S1888-9891(20)30033-1. doi: 10.1016/j.rpsm.2020.04.008
Fernandez-Egea E, Walker R, Ziauddeen H, Cardinal RN, Bullmore ET. Birth weight, family history of diabetes and diabetes onset in schizophrenia. BMJ Open Diabetes Research and Care. 2020; 8(10:e001036); 10.1136/bmjdrc-2019-001036
Toll A, Berge D, Burling K, Scoriels L, Treen D, Montserrat C, Marmol C, Duran X, Jones PB, Perez-Sola V, Fernandez-Egea E, Mane A. Cannabis use influence on peripheral brain-derived neutrophic factors levels in antipsychotic-naïve first-episode psychosis. Eur Arch Psychiatry Clin Neurosci, 2020; 270(7):851-858.
Atkinson-Clement C, Sofia F, Fernández-Egea E, de Liege A, Béranger B, Klein Y, Deniau E, Flamand E, Hartmann A, Worbe Y. Structural and functional abnormalities within sensori-motor and limbic networks underpin intermittent explosive symptoms in Tourette disorder. J Psych Res 2020, 125:1-6.
Jarratt-Barnham I, Saleh Y, Husain M, Kirkpatrick B, Fernandez-Egea E. The influence of negative and affective symptoms on anhedonia self-report in schizophrenia. Comprehensive Psychiatry 2020; 98:152165
Dal Santo F, Jarratt-Barnham I, González-Blanco L, García-Portilla MP, Bobes J, Fernández-Egea E. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: a mediation model. Eur Neuropsychopharmacology 2020; 33:158-163.
Daniels ND, Fernandez-Egea E. Sleepwalking associated with clozapine treatment: two cases. J Clin Psychopharmacology 2020; 40(3):305-306.
García-Rizo C, Bioque M, Mezquida G, Amoretti A, Cuesta MJ, Díaz-Caneja CM, Mas S, Lobo A, González-Pinto A, Fraguas D, Corripio I, Vieta E, Baeza I, Berge D, Fernandez-Egea E, Garriga M, Bernardo M and PEPs GROUP. Birth weight and antipsychotic induced weight gain: a prenatal programming approach in the PEPs study. Schizophr Res, 2020; 218:292-294
Mezquida G, Fernandez-Egea E, Treen D, Mane A, Berge D, Savulich G, Garcia-Alvarez L, Garcia-Portilla MP, Bobes J, Bernardo M, Garcia-Rizo M. Difficulties in delivery and depressive symptomatology in schizophrenia. Rev Psiquiatr Salud Mental 2021 14(1):66-68).
Kirkpatrick B, Gurbuz O, Delice M, Hack G, Fernandez-Egea E. An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia. Schizophrenia Bulletin 2019; 4596):1331-1335.
Biria M, Huang FX, Worbe Y, Fineberg NA, Robbins TW, Fernandez-Egea E. A cross sectional study of impact and risk factors of antipsychotic-induced OCD. Eur Neuropsychopharmacol 2019; 29(8):905-913.
Turrion MC, Perez J, Bernardo M, Fernandez-Egea E. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. Rev Psiquiatr Salud Mental 2020; 13(1):31-35.
Garriga M, Fernandez-Egea E, Mallorqui A, Serrano L, Oliveira C, Parellada E, Kirkpatrick B, Vieta E, Bernardo M, Garcia-Rizo C. Antipsychotic-induced weight gain and birth weight in psychosis: a fetal programming model. J Psychiatr Res 2019: 115:29-35.
Scoriels L, Zimbron J, Garcia-Leon N, Coll-Negre M, Giro M, Perez J, Jones PB, Fernandez-Egea E. Cross-sectional study of diet patterns in early and chronic schizophrenia. Schizophrenia Research 2019; 208:451-453.
Fernandez-Egea E. One hundred years ago: Nijinsky and the origins of schizophrenia. Brain, 2019; 142(1):220-226.
Nestor LJ, Paterson LM, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Ersche KD, Suckling J, Elliott R, Deakin B, Rabiner I, Lingford Hughes A, Sahakian BJ, Robbins TW, Nutt DJ; ICCAM Consortium. Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and poly-substance dependent individuals. Eur J Neuroscience 2019; 50(3): 2311-2321.
Mezquida G, Fernandez-Egea E, Treen D, Mane A, Berge D, Savulich G, Garcia-Alvarez L, Garcia-Portilla P, Bobes J, Bernardo M, Garcia-Rizo C. Obstetric phenotypes in the heterogeneity of schizophrenia. J Nerv Ment Dis, 2018: 206(11):882-886.
Treen D, Savulich G, Mezquida G, Garcia-Portilla MP, Toll A, Garcia-Rizo C, Garcia-Alvarez L, Berge D, Bobes J, Bernardo M, Fernandez-Egea E, Mane A. Influence of secondary sources in the brief negative symptom scale. Schizophrenia Research. 2019; 204:452-454.
Fernandez-Egea E, Worbe Y, Bernardo M, Robbins TW. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychological Medicine 2018; 48(16):2668-2675.
Ahmed A, Kirkpatrick B, Galderisi S, Mucci A, Maj M, Rossi A, Bertolino A, Rocca P, Kaiser S, Bischof M, Hartmann M, Kirschner M, Schneider K, Garcia-Portilla MP, Mane A, Bernardo M, Fernandez-Egea E, Jiefeng C, Jing Y, Gold JM, Allen DN, Strauss GP. Cross-cultural validation of the five-factor structure of negative symptoms in schizophrenia. Schizophrenia Bulletin 2019 45(2):305-314.
Savulich G, Mezquida G, Atkinson S, Bernardo M, Fernandez-Egea E. Clozapine and cognition: friend or foe? J Clin Psychopharmacology 2018 Apr; 38(2):152-153.
Fernandez-Egea E, Kirkpatrick B. Correspondence regarding two recent publications in npj:schizophrenia about DNAm and accelerated aging in schizophrenia. NPJ Schizophrenia 2017 3(1):38 doi: 10.1038/s41537-017-0041-5.
Garcia-Rizo C, Casanovas M, Fernandez-Egea E, Oliveira C, Meseguer A, Cabrera B, Mezquida G, Bioque M, Kirkpatrick B, Bernardo M. Blood Cell count in antipsycotic-naive patients with non-affective psychosis. Early Interv Psychiatry 2017 (doi 10.1111/eip.12456). PMID: 28786532
Mezquida G, Savulich G, Garcia-Rizo C, Garcia-Portilla MP, Toll A, Garcia-Alvarez L, Bobes J, Mané A, Bernardo M, Fernandez-Egea E. Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizo Res. 2018 Feb;192:69-74; PMID: 28412089.
Apergis-Schoute AM, Gillan CM, Fineberg NA, Fernandez-Egea E, Sahakian BJ, Robbins TW. Neural Basis of impaired safety signaling in Obsessive Compulsive Disorder. PNAS. 2017 Mar 21;114(12):3216-3221.
Garrison JR, Fernandez-Egea E, Zaman R, Agius M, Simons JS. Reality monitoring impairment in schizophrenia reflects specific prefrontal cortex dysfunction. Neuroimage Clin. 2017 25th January;14:260-268.
Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Castro-Fornieles J, Bergé D, Escartí MJ, Ibañez Á, Penadés R, Sánchez-Torres AM, Bernardo M; PEPs Group. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophr Res. 2017 Feb 6. pii: S0920-9964(17)30060-9.
Anderson EJ, Tibber MS, Schwarzkopf DS, Shergill SS, Fernandez-Egea E, Rees G, Dakin SC. Visual Population Receptive Fields in People with Schizophrenia Have Reduced Inhibitory Surrounds. J Neurosci. 2017 8th February;37(6):1546-1556.
Garcia-Rizo C, Fernandez-Egea E, Bernardo M, Kirkpatrick B. Metabolic syndrome or glucose challenge in first episode of psychosis? Eur Psychiatry 2017 Mar; 41:42-46.
Fernandez-Egea E, Vertes PE, Flint SM, Turner L, Mustafa S, Hatton A, Smith KG, Lyons PA, Bullmore ET. Peripheral Immune Cell Populations Associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PLOS One, 2016: 11(5):e0155631.
Mezquida G, Penades R, Cabrera B, Savulich G, Lobo A, Gonzalez-Pinto A, Penzol MJ, Corripio I, Fernandez-Egea E, Gasso P, Cuesta MJ, Bernardo M, PEPs group. Association of the brain-derived neurotrophic facotr Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia patients. Eur Psychiatry 2017 Oct;26(9):1353-1365.
Zimbron J, Khandaker G, Toschi C, Jones PB, Fernandez-Egea E. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic síndrome. Eur Neuropsychopharmacology 2016 (in press).
Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Bernardo M, Kirkpatrick B. Meta-analysis of glucose tolerance, insulin and insulin resistance in antipsychotic-naive patients with nonaffective psychosis. Schizo Res 2017 Jan; 179:57-63.
Brown JE, Mezquida G, Fernandez-Egea E. Well-being in clozapine-treated schizophrenia patients: the significance of positive symptoms. Compr Psychiatry 2016;68:140-146.
Ziauddeen H, Garcia-Rizo C, Bernardo M, Kirkpatrick B, Ozanne SE, Jones PB, Fernandez-Egea E. Association of Birth Weight and the Development of Antipsychotic Induced Adiposity in Individuals with Schizophrenia. Eur Neuropsychopharmacology 2016; 26(6):972-978.
Gonzalez-Blanco L, Greenhalgh AM, Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophrenia Res 2016; 174(1-3):156-160.
Perdigués SR, Quecuti RS, Mané A, Mundell C, Fernandez-Egea E. An observation study of clozapine induced sedation and its management. Eur Neuropsychopharmacol. 2016; 26(1):156-61.
Sauras-Quecuti R, Ramos-Perdigues S, Mann L, Fernandez-Egea E. A study of clozapine-induced sedation. Actas Esp Psychiatry (in press).
Garcia-Rizo C, Kirkpatrick B, Fernandez-Egea E, Bernardo M. Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. Psychoneuroendocrinology. 2016 Feb 12;67:70-75.
Cardinal RN, Savulich G, Mann L, Fernandez-Egea E. Association between antipsychotic/antidepressant drug treatment and hospital admissions in schizophrenia assessed using a mental health case register". Npj:schizophrenia 2015 131(1):18-20.
Garcia-Portilla MP, Garcia-Alvarez L, Mané A, Garcia-Rizo C, Sugranyes G, Bergé D, Bernardo M, Fernández-Egea E, Bobes J. "The negative syndrome of schizophrenia: Three -underlying components are better than two." Schizophr Res 2015; 166(1-3):115-118.
Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L,Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Passetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JW, Nutt DJ, Lingford-Hughes AR, ICCAM Platform (2015), "The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description." J Psychopharmacol 2015; 29(9): 943-960.
Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, Hafizi S, Perez J, Fernandez-Egea E, Suckling J, Jones PB. "The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people." Philos Trans R Soc Lond B Biol Sci 2015; 370(1677).
Worbe Y, Palminteri S, Savulich G, de Wit S, Fernandez-Egea E, Robbins TW, Voon V. Valence-dependent influence of serotonin depletion on model-based choice strategy. Mol Psychiatry 2016; 21(5):624-629.
Garcia-Rizo C, Fernandez-Egea E, Bernardo M, Kirkpatrick B. The thrifty phychiatric phenotype. Acta Psychiatrica Scandinavica 2015, 131(1):18-20
Worbe Y, Savulich G, deWitt S, Fernandez-Egea E, Robbins TW. Tryptophan depletion promotes habitual over goal-directed control of appetitive responding in humans. International Journal of Neuropsychopharmacology 2015; 18(10):pyv013.
Mane A, Garcia-Rizo C, Garcia-Portilla MP, Berge D, Sugranyes G, Garcia-Alvarez L, Bernardo M, Bobes J, Fernandez-Egea E. Spanish adaptation and validation of the Brief Negative Symptoms Scale. Comprehensive Psychiatry 2014 55 (7):1726-1729.
Ellison-Wright I, Nathan PJ, Bullmore ET, Zaman R, Dudas R, Agius M, Fernandez-Egea E, Muller U, Dodds CM, Forde N, Scanlon C, Leemans A, McDonald C, Cannon DM. Distribution of tract deficits in schizophrenia. BMC Psychiatry. 2014; 14(1):99.
Worbe Y, Savulich G, Voon V, Fernandez-Egea E, Robbins TW. Serotonin depletion induces "waiting impulsivity" on the human Four Choice Serial Reaction Time Task: Cross-species translational significance. Neuropsychopharmacology 2014; 39(6):1519-26.
Horga G, Fernandez-Egea E, Mane E, Font M, Schatz K, Falcon C, Lomena F, Bernardo M, Parellada E. Brain metabolism during hallucination-like auditory stimulation in schizophrenia. PLoS One 2014; 9(1):e84987.
Kaser M, Soltesz F, Lawrence P, Miller S, Dodd C, Croft R, Dudas R, Zaman R, Fernandez-Egea E, Muller U, Dean A, Bullmore E, Nathan P. Oscillatory Underpinnings of Mismatch Negativity and their Relationship with Cognitive Function in Patients with Schizophrenia. PLoS One 2013; 8(12):e83255.
Fernandez-Egea E, Scoriels L, Theegala S, Giro M, Ozanne SE, Burling K, Jones PB. Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2013; 46:25-28.
Garcia-Rizo C, Kirkpatrick B, Fernandez-Egea E, Oliveira C, Meseguer A, Grande I, Undurraga J, Vieta E, Bernardo M. "Is bipolar disorder an endocrine condition?" Glucose abnormalities in bipolar disorder. Acta Psychiatr Scand. 2014; 129(1):73-4.
Kirkpatrick B, Miller B, Garcia-Rizo C, Fernandez-Egea E. A conceptual model of schizophrenia. Clinical Schizophrenia and Related Psychosis Journal 2014; 8(2):73-79.
Batalla A, Garcia-Rizo C, Castellvi P, Fernandez-Egea E, Yucel M, Parellada E, Kirkpatrick B, Martin-Santos R, Bernardo M. Screening for substance use disorders in first-episode psychosis: implications for readmission. Schizophrenia Research. 2013;146(1-3):125-31.
Fernandez-Egea E, Garcia-Rizo C, Zimbron J, Kirkpatrick B. Diabetes or Prediabetes in Newly Diagnosed Patients With Nonaffective Psychosis? A Historical and Contemporary View. Schizophr Bull. 2013; 39(2):266-267.
Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Oliveira C, Justicia A, Griffith JK, Heaphy CM, Bernardo M, Kirkpatrick B. Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. Brain Behav Immun. 2013; 28:49-53.
Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs nondeficit features. Psychiatry Research 2012; 198(2):212-5.
Pons A, Romero A, Goti J, Fernandez-Egea E, Undurruaga J, Carne X, Bernardo M. Should obesity be a limiting factor for clozapine treatment? Rev Psiquiatr Salud Ment 2013; 6(2): 75-79.
Fernandez-Egea E, Parellada E, Sugranyes S, Horga G, Lomena F, Falcon C, Pavia J, Bernardo M. Left Amygdalar Activation With Deficit Syndrome compared to Nondeficit Subjects During the Control Task in a Facial Emotion Recognition Paradigm. Psychiatry Research 2012 30th July;203(1):109-10
Pintor L, Valldeoriola F, Fernandez-Egea E, Sanchez R, Rami L, Tolosa E, Muniz A, Marti MJ, Bernardo M. Utility of the Electroconvulsive Therapy in Parkinson's Disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study. J ECT. 2012 Jun;28(2):87-91.
Fernandez-Egea E, Garcia-Rizo C, Miller B, Justicia A, Parellada E, Bernardo M, Kirkpatrick B. Testosterone in Newly Diagnosed, Antipsychotic-Naïve Men with Nonaffective Psychosis: A Test of the Accelerated Aging Hypothesis. Psychosom Med. 2011 Oct;73(8):643-7.
Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, Kirkpatrick B. Prolactin in first episode of non affective psychosis: gender differences and implications. Schizophrenia Research 2012; 134 (1):16-19.
Mane A, Gallego J, Lomena F, Mateos JJ, Fernandez-Egea E, Horga G, Cot A, Pavia J, Bernardo M, Parellada E. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. Psychiatry Res. 2011; 194(1):79-84
Fernandez-Egea E, Miller B, Garcia-Rizo, Bernardo M, Kirkpatrick. Metabolic Effects of Olanzapine in Newly-Diagnosed patients with psychosis. Journal of Clinical Psychopharmacology 2011; 31(2): 154-159.
Horga G, Parellada E, Lomena F, Fernandez-Egea E, Mane A, Font M, Falcon C, Konova A, Pavia J, Ros D, Bernardo M. Differential brain glucose metabolic patterns in antipsychotic-naïve first-episode schizophrenia with and without auditory verbal hallucinations. J Psychiatry Neurosci. 2011 Sep;36(5):312-21.
Kirkpatrick B, Garcia-Rizo C, Tang K, Fernandez-Egea E, Bernardo M. Cholesterol and triglycerides in antipsychotic-naïve patients with nonaffective psychosis. Psychiatry Research 2010;178 (3): 559-561.
Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naïve patients with nonaffective psychosis confounded by poor health habits? Schizophr Bulletin 2012; 38(2):280-284
Serraga N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F, Gascon J, Soler-Insa PA, Menchon JM and Keefe RSE. Spanish Validation of the BACS (Brief Assessment in Cognition in Schizophrenia) in patients with schizophrenia and healthy controls. European Psychiatry 2011; 26(2): 69-73.
Fernandez-Egea E, Parellada E, Lomeña F, Falcon C, Pavia J, Bernardo M. Amygdalar dysfunctional hyperactivity in schizophrenic patients across facial emotional and non emotional recognition tasks. European Archives of Psychiatry and Clinical Neuroscience 2010; 260(1): 69-76
Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Stem Cell Signaling in Psychosis. Mol Psychiatry 2009; 14 (11): 989-991.
Mané A, Falcon C, Mateos JJ, Fernadez-Egea E, Horga G, Lomeña F, Bargallo N, Bernardo M, Parellada E. Progressive gray matter changes in first-episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. Schizophrenia Research 2009; 114 (1-3):136-143.
Cardinal RN, Shah DN, Edwards C, Hughes GRV, Fernandez-Egea E. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. British Journal Psychiatry 2009; 195(3):272. Letter.
Sugranyes G, Flamarique I, Parellada E, Baeza I, Fernandez-Egea E, Bernardo M. Cannabis abuse and age of psychosis onset. European Journal of Psychiatry 2009 2009; 24(5): 282-286.
Fernandez-Egea E, Bernardo M, Conget I, Donner T, Parellada E, Esmatjes E, Kirkpatrick B. The Metabolic Profile of Antipsychotic-Naïve Patients with Nonaffective. British Journal of Psychiatry 2009; 194 (5):434-438.
Fernández-Egea E, Bernardo M, Parellada E, Donner T, Kirkpatrick B et al. Telomere length, pulse pressure and glucose metabolism in schizophrenia. Schizophrenia Bulletin 2009; 35(2):437-442.
Kirkpatrick B, Fernandez-Egea E, Garcia-Rizo C, Bernardo M. Differences in Glucose Tolerance Between Deficit and Nondeficit schizophrenia. Schizophrenia Research 2009; 107:122-127.
Fernandez-Egea E, Parellada E, Lomeña F, Falcon C, Pavia J, Mané A, Valdes M, Bernardo M. Continuous emotional task selectively activates the left amygdala in healthy volunteers: 18FDG-Study. Psychiatry research: neuroimaging 2009; 171(3):199-206.
Parellada E, Lomena F, Font M, Pareto D, Gutierrez F, Simo M, Fernández-Egea E, Pavia J, Ros D, Bernardo M. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. Nucl Med Commun 2008 Oct; 29(10):894-900.
Fernandez-Egea E, Bernardo M, Parellada E, Justica A, García-Rizo C, Conget I, Esmatjes E, Kirkpatrick B. Glucose Abnormalities in the Siblings of People with Schizophrenia. Schizophrenia Research 2008; Aug; 103(1-3):110-3.
Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B. Parental History of Type 2 Diabetes in Patients with Nonaffective Psychosis. Schizophrenia Research 2008; 1-3:302-306.
Kirkpatrick B, Hack GD, Higginbottom E, Hoffacker D, Fernandez-Egea E. Palate and dentition in schizophrenia.Schizophrenia Research 2007; 91:187-191.
Mateos JJ, Lomeña F, Parellada E, Font M, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 2007; 191:805-811.
Pintor L, Bailles E, Fernandez-Egea E, Sanchez-Gistau V, Torres X, Carreno M, Rumia J, Matrai S, Boget T, Raspall T, Donaire A, Bargallo N, Setoain X. Psychiatric disorders in temporal lobe epilepsy patients over the first year after surgical treatment. Seizure: European Journal of Epilepsy 2007; 16:218-225.
Bernardo M, Fernández-Egea E, Torras A, Gutierrez F, Ahuir M, Arango C. Validation into Spanish of the Schedule for the Deficit Syndrome. [Adaptación y validación en castellano del Inventario para la Esquizofrenia Deficitaria]. Medicina Clinica (Barc) 2007;129:91-93.
Gomez-Gil E, Fernández-Egea E, Trilla A, Almela A. Relevance of routine luetic serological test in acute psychiatric patient [Relevancia de la serología luética en pacientes psiquiátricos agudos ingresados]. Medicina Clínica (Barc) 2007;129:77.
Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Bernardo M. [Striatal dopamine transporter density decrease in first-episode schizophrenic patients treated with risperidone]. Rev Esp Med Nucl. 2006;25(3):159-165.
Fernández-Egea E, A. Ferrer del Alamo, M. Torrebadell Buriel, A. Carrió Ybáñez. Velocardiofacial síndrome in consultant-liason psychiatry. [El Síndrome Velo Cardio Facial en el ámbito clínico.] Letter. Actas Esp Psiquiatr. 2006; 34(1):67-68.
Mateos JJ, Lomeña F, Parellada E, Font E, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M. Decreased striatal dopamine transporters binding assessed with [123I]FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (2005) 181: 401–406.
Bailles E, Pintor L, Fernández-Egea E, Torres X, Matrai S, de Pablo J, Arroyo S. Psychiatric disorders, trauma, and MMPI profile in a Spanish simple of nonepileptic seizure patients. Gen Hosp Psychiatry 2004; 26(4):310-315
Bailles E, Pintor L, Torres X, Fernández-Egea E, de Pablo J, Arroyo S. Patología psiquiátrica en pacientes con pseudocrisis remitidos a una unidad de epilepsia de un hospital general. [Psychiatric disease in patients with psychogenic non-epileptic seizures referred from an epilepsy unit in a general hospital] Spanish. Actas Esp Psiquiatr. 2004 Mar-Apr; 32(2):76-81
Parellada E, Lomena F, Catafau AM, Bernardo M, Font M, Fernández-Egea E, Pavia J, Gutierrez F. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Res. 2004; 130:79-84.
Gómez-Gil E, Vidal A, Panés J, Jaén J, Peri JM, Fernández-Egea E, Piqué JM. [Relationship between patient's subjective stress perception and the course of inflammatory bowel disease]. Spanish. Gastroenterol Hepatol. 2003; 26(7):411-6.
Font M, Parellada E, Fernández-Egea E, Bernardo M, Lomeña M. Neuroimaging of auditory hallucinations in schizophrenia. [Neuroimagen funcional de las alucinaciones auditivas en la esquizofrenia]. Review. Actas Españolas de Psiquiatría. 2003; 31: 3-9.
Gómez E, Trilla A, Corbella B, Fernández-Egea E, Pablo J, Ferrer J, Valdés M. Lack of clinical relevance of routine chest radiography in acute psychiatric admissions. General Hospital Psychiatry 2002; 24: 110-113.
Fernández-Egea E, Gómez Gil E, Corbella Santomà B, Salamero Baró M, Blanch J, Valdés Miyar M. Prevalence of HIV, BHV and CHV among acute psychiatric patients admitted. Medicina Clínica (Barc), 2002; 119: 690-962.
